1 / 10

Influenza Vaccine Manufacturing

Influenza Vaccine Manufacturing. Industry Perspective for 2014-15 NH Vaccine Supply.

amory
Télécharger la présentation

Influenza Vaccine Manufacturing

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Influenza Vaccine Manufacturing Industry Perspective for 2014-15 NH Vaccine Supply The FDA CBER requested this annual summary of information from influenza vaccine manufacturers supplying the U.S., for purposes of a general presentation to the VRBPAC. This summary has been prepared  from a variety of public sources, and was reviewed by AstraZeneca, bioCSL, GSK, Novartis, Protein Sciences, and Sanofi Pasteur.

  2. 2013-14 Influenza Vaccines • ~134 million doses distributed through 31 January 2014 and in line with 2012-13 season1 • Transition to quadrivalent influenza vaccine (QIV) began during 2013-14 season with QIV volume ~20% of total doses • QIV volume will likely increase to over 50% for the 2014-15 season • As the variety of influenza vaccines has increased in recent years, healthcare providers are choosing different presentations for different patients • Timely strain selection by VRBPAC in February 2013 was very helpful • Challenges • A(H3N2) recommendation was “an H3N2 virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011” (clarified for WHO 2014 SH and 2014-15 NH recommendations) Source: 1http://www.cdc.gov/flu/professionals/vaccination/vaccinesupply.htm (as of 12 Feb 2014) Industry Comments, VRBPAC 28 February 2014

  3. Vaccination Rates in 2012-13 Higher than in 2011-12 Source: http://www.cdc.gov/flu/fluvaxview/coverage-1213estimates.htm (as of 12 Feb 2014) Overall immunization rate of 45% for individuals 6 months of age and older during the 2012-13 season Significant increase in the 6 months - 17 years of age group (to 56.6%) Slight increase in the 18 years of age and older group (to 41.5%) Industry Comments, VRBPAC 28 February 2014

  4. Total Cumulative Influenza Vaccine Claims in 2013-14 Higher than in 2012-13 ~6% Data suggest 2013-14 immunizations are up ~6% vs. prior year Source: IMS Health Custom Study, Medical Claims Data, Week Ending 25 Jan 2014 Industry Comments, VRBPAC 28 February 2014

  5. Influenza Vaccine Strain Changes Industry Comments, VRBPAC 28 February 2014

  6. Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Annual License Approval Surveillance & Reassortants Vaccination Production (may be at risk) Formulation Production Filling & Packaging Distribution Influenza Vaccine Manufacturing Timeline Strain Selection Produce & Standardize Reagents FDA Production Strain Balancing Production (at risk) Produce Working Seed Production 4 4 4 Industry Comments, VRBPAC 28 February 2014

  7. Influenza Vaccine ManufacturingCritical Factors • Global timing of strain selection ensures large vaccine supply • Available time to manufacture influenza vaccine is determined by • Need to distribute & administer vaccine well before the peak season • Availability of last vaccine strain • To ensure timely availability of influenza vaccine, manufacturing of at least one strain starts at risk before VRBPAC recommendations • Productivity of the least productive monovalent strain determines supply quantity • Availability of potency test reagents • Complex process to prepare and standardize potency reagents for new strains • Linked to global timing of strain selection for new strains • Availability of calibrated reagents determines start of influenza vaccine formulation Industry Comments, VRBPAC 28 February 2014

  8. Vaccine Strains under Evaluation for2014-15 NH Vaccine • A(H1N1): A/California/7/2009-like • A/California/7/2009 and reassortants (IIV and LAIV) • A/Christchurch/16/2010 and reassortants (IIV) • A/Brisbane/10/2010 and reassortants • A(H3N2): A/Victoria/361/2011 cell-derived-like • A/Texas/50/2012 and reassortants (IIV and LAIV) • A/New York/39/2012 and reassortants • A/Almaty/2958/2013 and reassortants Industry Comments, VRBPAC 28 February 2014

  9. Vaccine Strains under Evaluation for2014-15 NH Vaccine • B Yamagata lineage • B/Massachusetts/2/2012 and reassortants (IIV and LAIV) • B Victoria lineage • B/Brisbane/60/2008 and reassortants (IIV and LAIV) • B/Hong Kong/259/2010 and reassortants (IIV) • B/Nevada/3/2011 and reassortants (IIV and LAIV) • B/Texas/2/2013 and reassortants Industry Comments, VRBPAC 28 February 2014

  10. Industry Agency Shared Responsibility for Successful Influenza Vaccine Production & Supply • Communication • Continued timely sharing of surveillance and candidate virus information • Bi-weekly WHO teleconferences key in challenging situations • Strain selection • Timely review and selection of the appropriate viral strains • Balanced consideration of strain surveillance, selection timing, and impact to vaccine availability • Virus and reagent availability • Early access of all reassortant labs (NYMC, NIBSC, bioCSL, AstraZeneca, etc) to wild-type viruses • Opportunity for manufacturers to evaluate growth characteristics of potential strain candidates • Availability of potency test reagents for new strains by June • Vaccine approval and release • Timely approval of annual license supplement • In-season lot review and release process Industry Comments, VRBPAC 28 February 2014

More Related